Health Canada grants Priority Review for volanesorsen NDS filing Volanesorsen could be the first approved treatment for patients with FCS OTTAWA, Sept. 12, 2017 (GLOBE NEWSWIRE) — Akcea Therapeutics Canada, the Canadian subsidiary of Akcea Therapeutics, Inc., an affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders, today announced the filing of a New Drug Submission (NDS) to Health Canada for volanesorsen, an investigational medicine for the treatment of familial chylomicronemia syndrome (FCS). Health Canada has also granted priority review for the volanesorsen NDS. Priority review provides […]